Novartis is targeting a pivotal role in the generalized myasthenia gravis (gMG) market with FABHALTA (iptacopan), an oral small-molecule inhibitor of complement Factor B. Iptacopan is designed to prevent formation of C3 and C5 convertases, thereby limiting downstream complement activation and immune-mediated tissue injury. The therapy is currently in Phase III development for anti-AChR–positive gMG patients who have shown insufficient response to second- or third-line standards of care. Novartis plans to submit Phase III data by 2027, positioning iptacopan as a potential first-in-class oral complement inhibitor for refractory gMG—a segment where approximately 15% of patients fail to achieve sustained remission under current regimens.

In ResearchAndMarkets.com’s ‘Dermatology Market – Global Forecast 2026–2032,’ Novartis AG is listed among the 16 leading players shaping the sector’s transformation. While the overall market expands from USD 59.52 billion in 2026 toward USD 106.95 billion by 2032 at a 10.24% CAGR, Novartis’s presence underscores its strategic positioning across diagnostic devices, systemic therapies and topical formulations. Investors should note the company’s potential to leverage real-world evidence generation and regional regulatory alignment to capture share in key regions—including the Americas and Asia-Pacific—where supply chain resilience and tailored commercialization models are paramount.